{"product_id":"mer-primary-care-conferences-internal-medicine-for-primary-care-addiction","title":"MER Primary Care Conferences Internal Medicine for Primary Care Addiction Cardio Derm May 15-17, 2026","description":"\u003cdiv class=\"akf-prod-title\"\u003e\r\n\u003ch1\u003eMER Primary Care Conferences: Internal Medicine for Primary Care – Addiction, Cardiology \u0026amp; Dermatology 2026 (Videos)\u003c\/h1\u003e\r\n\u003ch2\u003eComprehensive Primary Care Updates in Cardiology, Addiction Medicine, Dermatology, Coronary Artery Disease, Heart Failure, Hypertension, Skin Cancer, and Evidence-Based Internal Medicine\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eStrengthen your expertise in comprehensive outpatient care with \u003cstrong\u003eMER Primary Care Conferences: Internal Medicine for Primary Care – Addiction, Cardiology \u0026amp; Dermatology 2026\u003c\/strong\u003e, an evidence-based continuing medical education (CME) program developed by \u003cstrong\u003eMedical Education Resources (MER)\u003c\/strong\u003e. Designed specifically for office-based primary care clinicians, this multidisciplinary conference provides practical updates in cardiovascular medicine, addiction medicine, dermatology, and preventive internal medicine, enabling healthcare professionals to confidently diagnose, manage, and prevent common yet complex medical conditions encountered in daily practice.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eHeld \u003cstrong\u003eMay 15–17, 2026\u003c\/strong\u003e, at \u003cstrong\u003eSpringHill Suites Springdale\/Zion National Park, Zion, Utah\u003c\/strong\u003e, this educational program features expert-led lectures, clinical case discussions, and guideline-based reviews focused on modern cardiovascular risk assessment, substance use disorders, hypertension, heart failure, dermatologic diagnosis, and skin cancer detection.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eParticipants gain clinically relevant knowledge that can be immediately integrated into outpatient practice while remaining current with evolving evidence-based guidelines across multiple specialties essential to modern primary care.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eProduct Details\u003c\/h1\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse:\u003c\/strong\u003e Internal Medicine for Primary Care – Addiction, Cardiology \u0026amp; Dermatology 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eProvider:\u003c\/strong\u003e Medical Education Resources (MER)\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eConference Dates:\u003c\/strong\u003e May 15–17, 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLocation:\u003c\/strong\u003e SpringHill Suites Springdale\/Zion National Park, Zion, Utah, USA\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Videos\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eEducational Level:\u003c\/strong\u003e Intermediate to Advanced\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLearning Format:\u003c\/strong\u003e Expert Lectures, Clinical Case Discussions, Guideline Reviews\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eCourse Overview\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003ePrimary care physicians are increasingly responsible for managing chronic cardiovascular disease, substance use disorders, and common dermatologic conditions while coordinating preventive healthcare and long-term patient management. Continuous advances in clinical guidelines require clinicians to remain current with evolving recommendations for diagnosis, risk stratification, pharmacologic therapy, and preventive medicine.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eMER Internal Medicine for Primary Care – Addiction, Cardiology \u0026amp; Dermatology 2026\u003c\/strong\u003e delivers a comprehensive review of these essential disciplines through evidence-based presentations and practical clinical scenarios. Faculty members provide updated recommendations for coronary artery disease, hypertension, dyslipidemia, heart failure, addiction treatment, alcohol use disorder, opioid-related care, dermatologic diagnosis, acne management, skin cancer screening, and office-based dermatologic procedures.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe curriculum emphasizes practical decision-making, early disease recognition, patient counseling, and implementation of current clinical guidelines to improve patient outcomes in the primary care setting.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhat You'll Learn\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eAfter completing this course, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eEvaluate patients with suspected coronary artery disease using evidence-based diagnostic strategies.\u003c\/li\u003e\r\n \t\u003cli\u003eApply current lipid and cholesterol guidelines to reduce cardiovascular risk.\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnose and manage hypertension according to contemporary recommendations.\u003c\/li\u003e\r\n \t\u003cli\u003eOptimize pharmacologic and non-pharmacologic management of heart failure.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize and treat substance use disorders and alcohol use disorder.\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstand the evolving role of cannabinoids within the opioid crisis.\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify dermatologic manifestations of systemic diseases.\u003c\/li\u003e\r\n \t\u003cli\u003eDifferentiate benign from malignant skin lesions and perform appropriate office-based procedures.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eComprehensive Topics Covered\u003c\/h1\u003e\r\n\u003ch2\u003eCoronary Artery Disease (CAD)\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDevelop a systematic approach to evaluating patients with suspected coronary artery disease.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCoronary artery disease\u003c\/li\u003e\r\n \t\u003cli\u003eChest pain evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular risk assessment\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic testing\u003c\/li\u003e\r\n \t\u003cli\u003eStress testing\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary CT angiography\u003c\/li\u003e\r\n \t\u003cli\u003ePrevention strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty review current evidence for selecting appropriate diagnostic pathways and optimizing patient outcomes.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eLipid Management \u0026amp; Cardiovascular Prevention\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eStrengthen preventive cardiology strategies.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eLipid disorders\u003c\/li\u003e\r\n \t\u003cli\u003eCholesterol management\u003c\/li\u003e\r\n \t\u003cli\u003eASCVD prevention\u003c\/li\u003e\r\n \t\u003cli\u003eStatin therapy\u003c\/li\u003e\r\n \t\u003cli\u003eNon-statin therapies\u003c\/li\u003e\r\n \t\u003cli\u003eLifestyle modification\u003c\/li\u003e\r\n \t\u003cli\u003ePrimary prevention\u003c\/li\u003e\r\n \t\u003cli\u003eSecondary prevention\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eHypertension\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview current recommendations for diagnosis and treatment.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBlood pressure measurement\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension diagnosis\u003c\/li\u003e\r\n \t\u003cli\u003eResistant hypertension\u003c\/li\u003e\r\n \t\u003cli\u003eSecondary hypertension\u003c\/li\u003e\r\n \t\u003cli\u003eAntihypertensive medications\u003c\/li\u003e\r\n \t\u003cli\u003eLifestyle interventions\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular risk reduction\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eHeart Failure\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eUpdate your knowledge of contemporary heart failure management.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHeart failure with reduced ejection fraction (HFrEF)\u003c\/li\u003e\r\n \t\u003cli\u003eHeart failure with preserved ejection fraction (HFpEF)\u003c\/li\u003e\r\n \t\u003cli\u003eGuideline-directed medical therapy (GDMT)\u003c\/li\u003e\r\n \t\u003cli\u003eSGLT2 inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eARNI therapy\u003c\/li\u003e\r\n \t\u003cli\u003eDiuretics\u003c\/li\u003e\r\n \t\u003cli\u003eLong-term disease management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eAddiction Medicine\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eImprove recognition and management of substance use disorders.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eSubstance use disorders\u003c\/li\u003e\r\n \t\u003cli\u003eScreening tools\u003c\/li\u003e\r\n \t\u003cli\u003eBrief intervention\u003c\/li\u003e\r\n \t\u003cli\u003eMedication-assisted treatment\u003c\/li\u003e\r\n \t\u003cli\u003eRecovery strategies\u003c\/li\u003e\r\n \t\u003cli\u003eIntegrated behavioral care\u003c\/li\u003e\r\n \t\u003cli\u003eRelapse prevention\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty review evidence-based approaches for identifying and treating addiction in primary care.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eAlcohol Use Disorder\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eEnhance clinical management of alcohol dependence.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAlcohol use disorder\u003c\/li\u003e\r\n \t\u003cli\u003eScreening\u003c\/li\u003e\r\n \t\u003cli\u003eWithdrawal assessment\u003c\/li\u003e\r\n \t\u003cli\u003ePharmacologic treatment\u003c\/li\u003e\r\n \t\u003cli\u003eBehavioral interventions\u003c\/li\u003e\r\n \t\u003cli\u003eLong-term recovery\u003c\/li\u003e\r\n \t\u003cli\u003ePatient counseling\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eCannabinoids \u0026amp; the Opioid Crisis\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eExplore emerging evidence regarding cannabinoid use in modern addiction medicine.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMedical cannabinoids\u003c\/li\u003e\r\n \t\u003cli\u003eOpioid crisis\u003c\/li\u003e\r\n \t\u003cli\u003ePain management\u003c\/li\u003e\r\n \t\u003cli\u003eHarm reduction\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence-based prescribing\u003c\/li\u003e\r\n \t\u003cli\u003ePublic health considerations\u003c\/li\u003e\r\n \t\u003cli\u003eClinical controversies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eDermatology for Primary Care\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDevelop confidence in diagnosing common skin disorders.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCommon dermatologic diseases\u003c\/li\u003e\r\n \t\u003cli\u003eClinical skin examination\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic algorithms\u003c\/li\u003e\r\n \t\u003cli\u003eCutaneous manifestations\u003c\/li\u003e\r\n \t\u003cli\u003eInflammatory skin disorders\u003c\/li\u003e\r\n \t\u003cli\u003eOffice-based dermatology\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eAcne \u0026amp; Acneiform Disorders\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview evidence-based management of acne.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAcne vulgaris\u003c\/li\u003e\r\n \t\u003cli\u003eAcneiform eruptions\u003c\/li\u003e\r\n \t\u003cli\u003eTopical therapies\u003c\/li\u003e\r\n \t\u003cli\u003eOral antibiotics\u003c\/li\u003e\r\n \t\u003cli\u003eIsotretinoin\u003c\/li\u003e\r\n \t\u003cli\u003eHormonal therapy\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment algorithms\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eSkin Cancer \u0026amp; Skin Tumors\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eStrengthen early detection of cutaneous malignancies.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBasal cell carcinoma\u003c\/li\u003e\r\n \t\u003cli\u003eSquamous cell carcinoma\u003c\/li\u003e\r\n \t\u003cli\u003eMelanoma\u003c\/li\u003e\r\n \t\u003cli\u003eActinic keratosis\u003c\/li\u003e\r\n \t\u003cli\u003eBenign skin tumors\u003c\/li\u003e\r\n \t\u003cli\u003eSkin biopsy\u003c\/li\u003e\r\n \t\u003cli\u003eCryotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eOffice procedures\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty discuss practical approaches for recognizing suspicious lesions and determining appropriate treatment or referral.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eDermatologic Clues to Internal Disease\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eRecognize skin findings associated with systemic illness.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCutaneous markers\u003c\/li\u003e\r\n \t\u003cli\u003eAutoimmune diseases\u003c\/li\u003e\r\n \t\u003cli\u003eEndocrine disorders\u003c\/li\u003e\r\n \t\u003cli\u003eInfectious diseases\u003c\/li\u003e\r\n \t\u003cli\u003eConnective tissue diseases\u003c\/li\u003e\r\n \t\u003cli\u003eInternal medicine correlations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eLearning Objectives\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eUpon completion of this educational activity, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePerform evidence-based evaluation of patients with suspected coronary artery disease.\u003c\/li\u003e\r\n \t\u003cli\u003eImplement current cholesterol and lipid management guidelines for cardiovascular prevention.\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnose and manage hypertension using contemporary treatment recommendations.\u003c\/li\u003e\r\n \t\u003cli\u003eApply guideline-directed therapy for heart failure.\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify and treat substance use disorders and alcohol use disorder.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate the role of cannabinoids within opioid-related care.\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnose common dermatologic disorders using a structured clinical approach.\u003c\/li\u003e\r\n \t\u003cli\u003eDifferentiate benign from malignant skin tumors and detect precancerous skin lesions.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eEducational Highlights\u003c\/h1\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eInternal Medicine\u003c\/li\u003e\r\n \t\u003cli\u003ePrimary Care\u003c\/li\u003e\r\n \t\u003cli\u003eCoronary Artery Disease (CAD)\u003c\/li\u003e\r\n \t\u003cli\u003ePreventive Cardiology\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure\u003c\/li\u003e\r\n \t\u003cli\u003eLipid Management\u003c\/li\u003e\r\n \t\u003cli\u003eCholesterol Guidelines\u003c\/li\u003e\r\n \t\u003cli\u003eAddiction Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eSubstance Use Disorder\u003c\/li\u003e\r\n \t\u003cli\u003eAlcohol Use Disorder\u003c\/li\u003e\r\n \t\u003cli\u003eCannabinoids\u003c\/li\u003e\r\n \t\u003cli\u003eOpioid Crisis\u003c\/li\u003e\r\n \t\u003cli\u003eDermatology\u003c\/li\u003e\r\n \t\u003cli\u003eAcne\u003c\/li\u003e\r\n \t\u003cli\u003eSkin Cancer\u003c\/li\u003e\r\n \t\u003cli\u003eMelanoma\u003c\/li\u003e\r\n \t\u003cli\u003eDermatologic Procedures\u003c\/li\u003e\r\n \t\u003cli\u003ePreventive Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eContinuing Medical Education (CME)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhy This Course Stands Out\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eMER Internal Medicine for Primary Care – Addiction, Cardiology \u0026amp; Dermatology 2026\u003c\/strong\u003e combines three high-impact disciplines into a single comprehensive educational program tailored for busy primary care clinicians. By integrating the latest cardiovascular guidelines, addiction medicine advances, and dermatologic updates with practical outpatient management strategies, the course provides immediately applicable knowledge that enhances diagnostic accuracy, preventive care, and evidence-based treatment across a broad range of clinical conditions.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eTarget Audience\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThis educational activity is ideal for:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePrimary Care Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eInternal Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eFamily Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eCardiologists\u003c\/li\u003e\r\n \t\u003cli\u003eAddiction Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eDermatologists\u003c\/li\u003e\r\n \t\u003cli\u003eNurse Practitioners\u003c\/li\u003e\r\n \t\u003cli\u003ePhysician Assistants\u003c\/li\u003e\r\n \t\u003cli\u003ePreventive Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eHospitalists\u003c\/li\u003e\r\n \t\u003cli\u003eInternal Medicine Residents\u003c\/li\u003e\r\n \t\u003cli\u003eFamily Medicine Residents\u003c\/li\u003e\r\n \t\u003cli\u003eHealthcare Professionals involved in outpatient adult medicine\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhy Choose This Course?\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eWhether you practice primary care, internal medicine, family medicine, cardiology, addiction medicine, or dermatology, \u003cstrong\u003eMER Internal Medicine for Primary Care – Addiction, Cardiology \u0026amp; Dermatology 2026\u003c\/strong\u003e provides an outstanding evidence-based review of today's most relevant outpatient medical conditions. Featuring expert faculty, guideline-driven recommendations, practical clinical algorithms, and case-based discussions, this course equips clinicians to deliver high-quality, patient-centered care while remaining current with rapidly evolving standards of practice.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003e\u003c\/h2\u003e\r\n\u003ch3 data-path-to-node=\"8\"\u003e4. Topics\u003c\/h3\u003e\r\n\u003cp data-path-to-node=\"9\"\u003e\u003cb data-path-to-node=\"9\" data-index-in-node=\"0\"\u003eCardiology\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"10\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-323\" data-path-to-node=\"10,0,0\"\u003e\u003cspan data-path-to-node=\"10,0,0,0\"\u003e\u003cb data-path-to-node=\"10,0,0,0\" data-index-in-node=\"0\"\u003eWork-up of Patients with Suspected CAD\u003c\/b\u003e: Risk factor evaluation and risk assessment models; Test selection including ECG, echo, nuclear and newer imaging modalities (including discussion of appropriate use criteria–AUC); The usefulness of CT scanning; The role of bio markers and EBCT; \u003c\/span\u003e\u003cspan data-path-to-node=\"10,0,0,2\"\u003e\u003cspan class=\"citation-822\"\u003eSuspected CAD in special populations (women, diabetics, the elderly)\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"10,0,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-324\" data-path-to-node=\"10,1,0\"\u003e\u003cspan data-path-to-node=\"10,1,0,0\"\u003e\u003cb data-path-to-node=\"10,1,0,0\" data-index-in-node=\"0\"\u003ePrimary \u0026amp; Secondary Prevention of CAD\u003c\/b\u003e: Definitions; AHA\/ACC and other lipid guidelines updates; HDL Cholesterol: The good cholesterol?; Metabolic syndrome and\/or obesity; Who needs treatment and how much; The role of lifestyle changes, exercise and cardiac rehabilitation; Drug therapy updates; \u003c\/span\u003e\u003cspan data-path-to-node=\"10,1,0,2\"\u003e\u003cspan class=\"citation-821\"\u003eRisk calculation\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"10,1,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-325\" data-path-to-node=\"10,2,0\"\u003e\u003cspan data-path-to-node=\"10,2,0,0\"\u003e\u003cb data-path-to-node=\"10,2,0,0\" data-index-in-node=\"0\"\u003eHypertension\u003c\/b\u003e: The 2017 AHA\/ACC Hypertension Guidelines; The 2024 ESC Guidelines for hypertension; Approaches to treatment thresholds and goals; Choices for initial and combination therapy; Resistant hypertension; \u003c\/span\u003e\u003cspan data-path-to-node=\"10,2,0,2\"\u003e\u003cspan class=\"citation-820\"\u003eTreating special populations: diabetics, the elderly, patients with renal failure\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"10,2,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-326\" data-path-to-node=\"10,3,0\"\u003e\u003cspan data-path-to-node=\"10,3,0,0\"\u003e\u003cb data-path-to-node=\"10,3,0,0\" data-index-in-node=\"0\"\u003eHeart Failure\u003c\/b\u003e: Etiologies and stages of heart failure; ACC\/AHA Heart Failure Guidelines; Heart failure with reduced EF (HFrEF) and heart failure with preserved EF (HFpEF); Determining patients for referral using biomarkers, eg NT Pro BNP; Treatment options: ACE inhibitors, ARBS, ARNI, beta blockers, mineralocorticoid receptor antagonists, SGLT2i; The role of devices in treatment and antiplatelet drugs; \u003c\/span\u003e\u003cspan data-path-to-node=\"10,3,0,2\"\u003e\u003cspan class=\"citation-819\"\u003eIssues related to the hospitalized patient with acute decompensated heart failure and readmissions\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"10,3,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-path-to-node=\"11\"\u003e\u003cb data-path-to-node=\"11\" data-index-in-node=\"0\"\u003eAddiction\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"12\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-327\" data-path-to-node=\"12,0,0\"\u003e\u003cspan data-path-to-node=\"12,0,0,0\"\u003e\u003cb data-path-to-node=\"12,0,0,0\" data-index-in-node=\"0\"\u003eSubstance Use and Addiction: Screening and Brief Intervention\u003c\/b\u003e: Essential information and skills needed for identifying substance use concerns; Epidemiology, screening tools and the stages of change; \u003c\/span\u003e\u003cspan data-path-to-node=\"12,0,0,2\"\u003e\u003cspan class=\"citation-818\"\u003ePractical steps for initial intervention in the primary care setting\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"12,0,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-328\" data-path-to-node=\"12,1,0\"\u003e\u003cspan data-path-to-node=\"12,1,0,0\"\u003e\u003cb data-path-to-node=\"12,1,0,0\" data-index-in-node=\"0\"\u003eAddiction Psychopharmacology for Alcohol Use Disorder\u003c\/b\u003e: The scope of alcohol related problems and the societal burden of Alcohol Use Disorder; \u003c\/span\u003e\u003cspan data-path-to-node=\"12,1,0,2\"\u003e\u003cspan class=\"citation-817\"\u003eOverview of FDA-approved as well as pertinent off-label pharmacotherapies for Alcohol Use Disorder\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"12,1,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-329\" data-path-to-node=\"12,2,0\"\u003e\u003cspan data-path-to-node=\"12,2,0,0\"\u003e\u003cb data-path-to-node=\"12,2,0,0\" data-index-in-node=\"0\"\u003eSubstance Use and Addiction: Diagnosis and Treatment\u003c\/b\u003e: Definition of addiction and its neurobiological basis; Examination of the diagnosis of substance use disorder and ASAM’s multidimensional assessment; Treatment and relapse challenges; \u003c\/span\u003e\u003cspan data-path-to-node=\"12,2,0,2\"\u003e\u003cspan class=\"citation-816\"\u003eThe use of motivational interviewing\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"12,2,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-330\" data-path-to-node=\"12,3,0\"\u003e\u003cspan data-path-to-node=\"12,3,0,0\"\u003e\u003cb data-path-to-node=\"12,3,0,0\" data-index-in-node=\"0\"\u003eAddiction Psychopharmacology for Opioid Use Disorder\u003c\/b\u003e: Opioid crisis update; Assessing risk factors for opioid overdose; FDA approved medication for treating overdose; \u003c\/span\u003e\u003cspan data-path-to-node=\"12,3,0,2\"\u003e\u003cspan class=\"citation-815\"\u003eFDA approved medication assisted treatment options for managing opioid addiction\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"12,3,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-path-to-node=\"13\"\u003e\u003cb data-path-to-node=\"13\" data-index-in-node=\"0\"\u003eDermatology\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"14\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-331\" data-path-to-node=\"14,0,0\"\u003e\u003cspan data-path-to-node=\"14,0,0,0\"\u003e\u003cb data-path-to-node=\"14,0,0,0\" data-index-in-node=\"0\"\u003eSkin Manifestations of Systemic Disease\u003c\/b\u003e: Skin will often reflect signs of systemic diseases, be useful for diagnosis, or suffer from a complication of disease or its treatment; \u003c\/span\u003e\u003cspan data-path-to-node=\"14,0,0,2\"\u003e\u003cspan class=\"citation-814\"\u003eDiagnosis of rheumatalogic, endocrine, gastrointestinal, and psychologic conditions based on cutaneous findings\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"14,0,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-332\" data-path-to-node=\"14,1,0\"\u003e\u003cspan data-path-to-node=\"14,1,0,0\"\u003e\u003cb data-path-to-node=\"14,1,0,0\" data-index-in-node=\"0\"\u003eAcne and Acneiform Eruptions\u003c\/b\u003e: Identification of noninflammatory open or closed comedones and inflammatory lesions; Determination of treatment therapies based on acne grading scale; Bacterial folliculitis, drug-induced acne, hidradenitis suppurativa, miliaria, perioral dermatits, pseudofolliculitis barbae, rosacea, seborrheic dermatitis; \u003c\/span\u003e\u003cspan data-path-to-node=\"14,1,0,2\"\u003e\u003cspan class=\"citation-812\"\u003eTopical and systemic \u003c\/span\u003e\u003cspan class=\"citation-812 citation-813 citation-end-813\"\u003etherapy\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"14,1,0,4\"\u003e\u003cspan class=\"citation-811 citation-end-811\"\u003e.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-333\" data-path-to-node=\"14,2,0\"\u003e\u003cspan data-path-to-node=\"14,2,0,0\"\u003e\u003cb data-path-to-node=\"14,2,0,0\" data-index-in-node=\"0\"\u003e\u003cspan class=\"citation-810\"\u003eBenign Skin Tumors\u003c\/span\u003e\u003c\/b\u003e\u003cspan class=\"citation-810 citation-end-810\"\u003e: Proper diagnosis and treatment of common benign tumors; Biopsies and histopathologic examination; Nevi, seborrheic keratosis keloids, hemangiomas and miscellaneous tumors; \u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"14,2,0,2\"\u003e\u003cspan class=\"citation-808 citation-809 citation-end-809\"\u003eWhen to refer\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"14,2,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_16b68616d1c8f960-334\" data-path-to-node=\"14,3,0\"\u003e\u003cspan data-path-to-node=\"14,3,0,0\"\u003e\u003cb data-path-to-node=\"14,3,0,0\" data-index-in-node=\"0\"\u003ePremalignant and Malignant Skin Tumors\u003c\/b\u003e: Recognition of precursors of malignancies; Excisional and punch biopsies; Actinic keratosis, Bowen’s disease, squamous cell carcinoma, basal cell carcinoma, melanoma and other selected tumors; \u003c\/span\u003e\u003cspan data-path-to-node=\"14,3,0,2\"\u003e\u003cspan class=\"citation-807\"\u003eRisk reduction education\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-path-to-node=\"14,3,0,4\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e","brand":"Meducourse","offers":[{"title":"Default Title","offer_id":43163712553058,"sku":"MED-AMB09719","price":100.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/MER-Primary-Care-Conferences-Internal-Medicine-for-Primary-Care-Addiction-Cardio-Derm-May-15-17-2026.jpg?v=1785419562","url":"https:\/\/meducourse.com\/products\/mer-primary-care-conferences-internal-medicine-for-primary-care-addiction","provider":"Meducourse","version":"1.0","type":"link"}